01 / DESIGN
What was studied?
Engineered receptor-expressing cells were used to compare kisspeptin-10, kisspeptin-54 and the synthetic C6 analog.
02 / FINDINGS
What did the researchers report?
C6 produced more sustained calcium and transcriptional responses together with greater tachyphylaxis. Responses to repeat stimulation differed across the molecules.
03 / LIMITS
How should it be interpreted?
Stronger signaling is not a direct ranking of clinical benefit. Distinct molecular forms cannot be treated as interchangeable evidence for a kisspeptin-10 product.
Voltera Peptide editorial reading note. Based on the linked source record. Methods and corrections.